Navitas Powers AI and EVs with Gen-3 'Fast' SiC in Robust TOLL Package
Newsfilter· 2024-08-01 20:30
TORRANCE, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Navitas Semiconductor (NASDAQ:NVTS), the industry leader in next-generation GaNFast™ gallium nitride (GaN) and GeneSiC™ silicon carbide (SiC) power semiconductors, today extended its new portfolio of Gen-3 ‘Fast' (G3F) 650 V SiC MOSFETs into a thermally-enhanced, rugged, high-speed, surface-mount TOLL (Transistor Outline Leadless) package designed for demanding, high-power, high-reliability applications. Combining high-power capability and best-in-class lo ...
Standard Motor Products, Inc. Announces Second Quarter 2024 Results and Quarterly Dividend
Prnewswire· 2024-08-01 20:30
NEW YORK, Aug. 1, 2024 /PRNewswire/ -- Standard Motor Products, Inc. (NYSE: SMP), a leading automotive parts manufacturer and distributor, reported today its consolidated financial results for the three and six months ended June 30, 2024. Net sales for the second quarter of 2024 were $389.8 million, compared to consolidated net sales of $353.1 million during the comparable quarter in 2023. Earnings from continuing operations for the second quarter of 2024 were $18.0 million or $0.81 per diluted share, compa ...
Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Newsfilter· 2024-08-01 20:30
Soquelitinib registrational Phase 3 clinical trial in PTCL advancing toward initial enrollment in Q3 2024 Fast track designation underscores unmet need for patients with relapsed or refractory PTCL, an indication with poor overall outcomes and no approved drugs based on randomized trials BURLINGAME, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ:CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and ...
Microbot Medical and Emory University to Evaluate the Future Autonomous Capabilities of the LIBERTY® Endovascular Robotic Surgical System
Newsfilter· 2024-08-01 20:30
BRAINTREE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT) today announced it has entered into an agreement with Emory University, which will allow the parties to evaluate and explore the potential for a future collaboration in connection with autonomous robotics in endovascular procedures. Under the terms of the agreement, Emory University will assume the responsibility of exploring the feasibility of integrating the LIBERTY® Endovascular Robotic Surgical System with an imaging ...
Carver Bancorp, Inc. Interim CEO Craig C. MacKay Comments on the Bank's 2024 Fiscal Year-End Performance
Prnewswire· 2024-08-01 20:30
NEW YORK, Aug. 1, 2024 /PRNewswire/ -- Carver Bancorp, Inc. (Nasdaq: CARV), the holding company for Carver Federal Savings Bank, released a letter from its Interim CEO Craig C. MacKay on the Bank's 2024 fiscal year-end performance:Dear Carver Shareholders: We remain optimistic about the Bank's future - Craig C. MacKay Post this Carver Bancorp, Inc. Interim CEO Craig C. MacKay Comments on the Bank's 2024 Fiscal Year-End Performance Carver Bancorp, Inc. ("Carver") reduced its net loss by 32% to $3.0 mill ...
PainReform's New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature
Newsfilter· 2024-08-01 20:30
TEL AVIV, Israel, Aug. 01, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (NASDAQ:PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, announces a major advancement in the development of its lead asset, PRF-110. The Company's new highly scalable manufacturing process, for which it recently filed a new patent, has enabled PRF-110 to achieve full product stability for 18 months at room temperature. This stability study is ...
Cellebrite Appoints Renowned Cybersecurity Expert Sigalit Shavit as Chief Information Officer
Newsfilter· 2024-08-01 20:30
文章核心观点 - 赛莱布莱特公司任命Sigalit Shavit为首席信息官(CIO),她将在公司领导团队中发挥关键作用,帮助公司加强创新能力和客户支持 [1][2][3][4] - Shavit拥有30多年的信息技术和安全经验,曾在FedEx Express、CyberArk等公司担任过CIO和COO等高级职位 [5] - Shavit将专注于确保赛莱布莱特的信息技术和安全组织能够持续满足业务需求,应对不断变化的网络威胁,并利用人工智能加速创新 [3][4][6] 公司概况 - 赛莱布莱特是一家为公共和私营部门提供数字调查解决方案的全球领导者 [7] - 公司的使命是帮助客户保护和拯救生命、加速司法正义和维护社区隐私 [7] - 赛莱布莱特的数字调查平台和解决方案可以帮助客户更高效地收集、审查、分析和管理合法调查中的数据 [7] 新任CIO简介 - Sigalit Shavit是一位经验丰富的信息技术和安全专家,曾在多家知名企业担任过高级管理职位 [5] - 在CyberArk任职期间,她在公司向企业级云/SaaS转型中发挥了关键作用 [5] - Shavit对于赛莱布莱特的使命感到非常兴奋,将致力于制定清晰的现代数字战略和解决方案,提高效率并加速创新 [6]
Intelligent Bio Solutions Partners with CenExel to Conduct Clinical Study as Part of FDA 510(k) Pathway
Newsfilter· 2024-08-01 20:30
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its partnership with CenExel, a nationwide clinical research site network, to perform a method comparison clinical study as part of the Company's FDA 510(k) clinical study plan. The Company's method comparison study will recruit 135 healthy adult subjects across three sites under an IRB- ...
Entera's EB613, the First Once Daily PTH(1-34) Tablet Treatment Dedicated to Post-Menopausal Women with High Risk Osteoporosis Abstract Selected for Presentation at the ASBMR 2024 Annual Meeting - Key SABRE Update Also Expected
Newsfilter· 2024-08-01 20:30
JERUSALEM, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of orally delivered peptides and therapeutic proteins, today announced that new comparative pharmacological data for its investigational agent EB613 vs. Forteo® was selected for presentation at the American Society for Bone and Mineral Research (ASBMR) 2024 Annual Meeting which will be held on September 27-30, 2024 in Toronto, ON, Canada. EB613 is being developed as the first o ...
Inuvo to Host Second Quarter 2024 Financial Results Conference Call on Thursday, August 8th at 4:15 P.M. ET
Newsfilter· 2024-08-01 20:30
LITTLE ROCK, Ark., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Inuvo, Inc. (NYSE:INUV), provider of the first generative artificial intelligence (AI) advertiser solution made specifically for brands and agencies, will host a conference call on Thursday, August 8, 2024, at 4:15 PM Eastern Time to discuss its financial results and provide a business update for the for the second quarter ended June 30, 2024. Conference Call Details: Date: Thursday, August 8, 2024Time: 4:15 p.m. Eastern Time Toll-free Dial-in Number: 1-8 ...
